DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.
Also called NCT04218656
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 159 participants
- Registry
-
NCT04218656
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT04218656. Non-randomized; no masking; primary purpose treatment. Start 2020-06-08 (actual); primary completion 2021-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
- Acronym
- DUAL-PAD
- Condition
- Peripheral Artery Disease
- Intervention (Drug)
- Rivaroxaban 2.5 Mg Oral Tablet
- Lead sponsor
- Radboud University Medical Center
Record details
- Record id
cardio:ct-nct04218656- Content hash
8a9a43d5495735ad852aabb6efc422acb6e60758186315ee3d6933ac28e658a7